Journal of Korean Biological Nursing Science

Korean society of Biological Nursing Science (한국기초간호학회)
권호 표지
DOI QR코드

DOI QR Code

Neurodegenerative Dementias: A Brief Review

  • Received : 2020.06.28
  • Accepted : 2020.08.06
  • Published : 2020.08.31
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: The purpose of this paper is to provide nurses with a concise review on neurodegenrative dementias. This review includes pathophysiology, clinical course, and tips on management of dementias from Alzheimer's disease (AD), Parkinson disease (PD) and lewy body dementia (LBD). Considering increasing numbers of dementia cases among older adults, nurses who are cognizant about dementia care are instrumental in maximizing daily activities and quality of life of patients with cognitive impairment and dementia.

Keywords

References

  1. Lopez OL, Kuller LH. Epidemiology of aging and associated cognitive disorders: prevalence and incidence of Alzheimer's disease and other dementias. In Dekosky ST, Asthana S, editor. Handbook of Clinical Neurology. Amsterdam: Elsevier; 2019. p.139-148.
  2. Ganguly G, Chakrabarti S, Chatterjee U, Saso L. Proteinopathy, oxidative stress and mitochondrial dysfunction: cross talk in Alzheimer's disease and Parkinson's disease. Drug Design, Development and Therapy. 2017;11:797-810. https://doi.org/10.2147/DDDT.S130514
  3. Lee G, Cummings J, Decourt B, Leverenz JB, Sabbagh MN. Clinical drug development for dementia with Lewy bodies: past and present. Expert Opinion on Investigational Drugs.2019;28(11):951-965. https://doi.org/10.1080/13543784.2019.1681398
  4. Jankovic J. Parkinson's disease: clinical features and diagnosis. Journal of Neurology, Neurosurgery, and Psychiatry. 2008;79(4):368-376. https://doi.org/10.1136/jnnp.2007.131045
  5. Chakrabarti S, Khemka KV, Banerjee A, Chatterjee G, Ganguly A, Biswas A. Metabolic risk factors of sporadic Alzheimer's disease: implications in the pathology, pathogenesis and treatment. Aging and Disease. 2015;6(4):282-299. https://doi.org/10.14336/AD.2014.002
  6. Dubbioso R, Manganelli F, Siebner HR, Lazzaro VD. Fast intracortical sensory-motor integration: a window into the pathophysiology of Parkinson's disease. Frontiers in Human Neuroscience. 2019;13:111. https://doi.org/10.3389/fnhum.2019.00111
  7. Chou KL, Hurtig HI, Eichler AF. Diagnosis and differential diagnosis of Parkinson disease. Alphen aan den Rijn: Wolters Kluwer; 2020 [cited 2020 June 19]. Available from: https://www.uptodate.com/contents/diagnosis-and-differential-diagnosis-of-parkinson-disease#H130396564.
  8. Truini A, Frontoni M, Cruccu G. Parkinson's disease related pain: a review of recent findings. Journal of Neurology. 2013;260(1):330-334. https://doi.org/10.1007/s00415-012-6754-5
  9. Gale SA, Acar D, Daffner KR. Dementia. American Journal of Medicine. 2018;131(10):1161-1169. https://doi.org/10.1016/j.amjmed.2018.01.022
  10. Malpetti M, Kievit RA, Passamonti L, Jones PS, Tsvetanov KA, Rittman T, et al. Microglial activation and tau burden predict cognitive decline in Alzheimer's disease. Brain: A Journal of Neurology.2020;143(5):1588-1602. https://doi.org/10.1093/brain/awaa088
  11. Davis Phinney Foundation. The difference between lewy body dementia, parkinson's disease and alzheimer's disease [Internet]. Louisville (CO): Davis Phinney Foundation; 2018[cited 2020 June 18]. Available from: https://www.davisphinneyfoundation.org/blog/difference-lewy-body-dementia-parkinsons-disease-alzheimers-disease/.
  12. McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017;89(1):88-100. https://doi.org/10.1212/WNL.0000000000004058
  13. Chan PC, Lee HH, Hong CT, Hu CJ, Wu D. REM sleep behavior disorder (RBD) in dementia with Lewy Bodies (DLB). Behavioural Neurology. 2018;2018:9421098. https://doi.org/10.1155/2018/9421098
  14. Massa F, Arnaldi D, De Cesari F, Girtler N, Brugnolo A, Grazzini M, et al. Neuroimaging findings and clinical trajectories of Lewy body disease in patients with MCI. Neurobiology of Aging. 2019;76:9-17. https://doi.org/10.1016/j.neurobiolaging.2018.12.001
  15. Bruijnen CJWH, Dijkstra BAG, Walvoort SJW, Budy MJJ, Beurmanjer H, De Jong C, et al. Psychometric properties of the Montreal Cognitive Assessment (MoCA) in healthy participants aged 18-70. International Journal of Psychiatry in Clinical Practice. 2020;9:1-8. https://doi.org/10.1080/13651501.2020.1746348
  16. Nasreddine ZS, Patel BB. Validation of Montreal Cognitive Assessment, MoCA, alternate French versions. The Canadian Journal of Neurological Sciences. 2016;43(5):665-671. https://doi.org/10.1017/cjn.2016.273
  17. Teng EL, Hasegawa K, Homma A, Imai Y, Graves A, Sugimoto K, et al. The Cognitive Abilities Screening Instrument (CASI): a practical test for cross-cultural epidemiological studies of dementia. International Psychogeriatrics. 1994;6(1):45-58; https://doi.org/10.1017/s1041610294001602
  18. Chiu EC, Yip PK, Woo P, Lin YT. Test-retest reliability and minimal detectable change of the Cognitive Abilities Screening Instrument in patients with dementia. PloS One. 2019;14(5):e0216450. https://doi.org/10.1371/journal.pone.0216450
  19. Butler M, Nelson VA, Davila H, Ratner E, Fink HA, Hemmy LS. et al. Over-the-counter supplement interventions to prevent cognitive decline, mild cognitive impairment, and clinical Alzheimer-type dmentia: a systematic review. Annals of Internal Medicine. 2018;168(1):52-62. https://doi.org/10.7326/M17-1530
  20. Leroi I, Vatter S, Carter LA, Smith SJ, Orgeta V, Pliakoff E, et al. Parkinson's-adapted cognitive stimulation therapy: a pilot randomized controlled clinical trial. Therapeutic Advances in Neurological Disorders. 2019;12:1756286419852217. https://doi.org/10.1177/1756286419852217
  21. Rose N, Whitworth A, Smart S, Oliver E, Cartwright J. "I remember when…": The impact of reminiscence therapy on discourse production in older adults with cognitive impairment. International Journal of Language and Pathology. 2020;22(3):359-371 https://doi.org/10.1080/17549507.2020.1747542.
  22. Sanford AM. Mild cognitive impairment. Clinics in Geriatric Medicine. 2017;33(3):325-337. https://doi.org/10.1016/j.cger.2017.02.005
  23. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman H.H. Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & Dementia: The Journal of the Alzheimer's Association. 2011;7(3):270-279. https://doi.org/10.1016/j.jalz.2011.03.008
  24. Langa KM, Levine D. The diagnosis and management of mild cognitive impairment: a clinical review. Journal of the American Medical Association. 2014;312(23):2551-2561. https://doi.org/10.1001/jama.2014.13806
  25. Morley JE. An overview of cognitive impairment. Clinics in Geriatric Medicine. 2018;34(4):505-513. https://doi.org/10.1016/j.cger.2018.06.003
  26. Prendecki M, Kowalska M, Toton E, Kozubski W. Genetic editing and pharmacogenetics in current and future therapy of neurocognitive disorders. Current Alzheimer Research. 2020;17(3):238-258. https://doi.org/10.2174/1567205017666200422152440
  27. Joe E, Ringman JM. Cognitive symptoms of Alzheimer's disease: clinical management and prevention. British Medical Journal. 2019;367:l6217. https://doi.org/10.1136/bmj.l6217